A Nomogram for the Determination of the Necessity of Concurrent Chemotherapy in Patients With Stage II–IVa Nasopharyngeal Carcinoma

Kaixuan Yang1,2, Qian Zhang1*, Mengxi Zhang2, Wenji Xie3, Mei Li2, Lei Zeng2, Qiang Wang2, Jianling Zhao2, Yiping Li2 and Guangjun Li2*

1 Department of Gynecology and Obstetrics, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China, 2 Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 3 Department of Radiation Oncology, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

**Background:** The efficiency of concurrent chemotherapy (CC) remains controversial for stage II–IVa nasopharyngeal carcinoma (NPC) patients treated with induction chemotherapy (IC) followed by intensity-modulated radiotherapy (IMRT). Therefore, we aimed to propose a nomogram to identify patients who would benefit from CC.

**Methods:** A total of 434 NPC patients (stage II–IVa) treated with IC followed by IMRT between January 2010 and December 2015 were included. There were 808 dosimetric parameters extracted by the in-house script for each patient. A dosimetric signature was developed with the least absolute shrinkage and selection operator algorithm. A nomogram was built by incorporating clinical factors and dosimetric signature using Cox regression to predict recurrence-free survival (RFS). The C-index was used to evaluate the performance of the nomogram. The patients were stratified into low- and high-risk recurrence according to the optimal cutoff of risk score.

**Results:** The nomogram incorporating age, TNM stage, and dosimetric signature yielded a C-index of 0.719 (95% confidence interval, 0.658–0.78). In the low-risk group, CC was associated with a 9.4% increase of 5-year locoregional RFS and an 8.8% increase of 5-year overall survival (OS), whereas it was not significantly associated with an improvement of locoregional RFS (LRFS) and OS in the high-risk group. However, in the high-risk group, patients could benefit from adjuvant chemotherapy (AC) by improving 33.6% of the 5-year LRFS.

**Conclusions:** The nomogram performed an individualized risk quantification of RFS in patients with stage II–IVa NPC treated with IC followed by IMRT. Patients with low risk could benefit from CC, whereas patients with high risk may require additional AC.

**Keywords:** nasopharyngeal carcinoma, intensity-modulated radiotherapy, concurrent chemotherapy, nomogram, chemoradiotherapy
INTRODUCTION

The cases of newly diagnosed nasopharyngeal carcinoma (NPC) reached about 129,000 in 2018 (1). More than 70% of NPC patients are in the east and southeast Asia. NPC is relatively sensitive to radiotherapy; radiotherapy is the mainstay treatment modality for nonmetastatic disease. As for stage II–IVa NPC, concurrent chemotherapy (CC) combined with radiotherapy is used to enhance radiosensitivity and local control. In the two-dimensional (2D) radiotherapy era, concurrent chemoradiotherapy (CCRT) is superior to radiotherapy in patients with stage III–IVa disease for progression-free survival (PFS) and overall survival (OS) (2). Stage II disease could also benefit from CCRT in terms of PFS and OS compared with radiotherapy alone in the 5- and 10-year follow-up (3, 4). Therefore, CCRT is widely accepted for treating stage II–IVa NPC (5).

Over time, radiotherapy modality has progressed from conventional 2D radiotherapy to 3D conformal radiotherapy and then to intensity-modulated radiotherapy (IMRT) for NPC. Recently, evidence from retrospective studies has shown that induction chemotherapy (IC) plus IMRT was superior to IC plus CCRT, with comparable survival outcomes and fewer acute toxic effects in treating stage II–IVa NPC (6). Notably, CCRT has a potential risk to increase the incidence of grade 3/4 acute toxicities (2, 6) and radiotherapy time, which adversely affect the survival of NPC (7). Therefore, it is critical to determine whether patients treated with IC followed by IMRT can benefit from CC. This can greatly enhance clinical decision-making.

IMRT is an advanced type of radiation therapy to conform the radiation dose to the tumor and to avoid the exposure of organs at risk (OARs) to enhance the therapeutic ratio. However, it is still challenging because of the anatomical proximity of gross tumor to OARs (8). Therefore, dosimetric inadequacy of target volumes that resulted from prescription constraints on critical OARs has been one of the most crucial independent prognosticators of survival outcomes of NPC (8–10). Dosimetric factors are commonly used to quantify the prescription isodose line coverage to the corresponding target volume and utilized to evaluate the plan quality among various radiotherapy approaches (11). It may improve patient care, too, by incorporating big data of dosimetric factors into clinical practice based on dose–volume histogram metrics of treatment plan (12, 13). In addition, dosimetric factors are regarded as score criteria for radiotherapy plan comparison in the International Radiotherapy Plan Competition (https://radiationknowledge.org/). Therefore, precision medicine needs to quantify clinical treatment plans based on dosimetric factors.

In this study, we aimed at developing a prognostic nomogram based on IMRT dosimetric signature as a risk quantification model and further identifying patient subsets who can benefit from CC in patients with stage II–IVa NPC treated with IC followed by IMRT.

MATERIALS AND METHODS

Study Workflow

Figure 1 shows the workflow of this study, including (1) radiotherapy planning data restored, (2) dosimetric parameter extraction by in-house script, (3) dosimetric signature building, and (4) nomogram development and risk stratification for concurrent chemotherapy.

Patients

This study was approved by our institutional review board, and the informed consent was waived because of the retrospective...
nature of this study. A dataset of 523 patients with stage II–IVA NPC (AJCC/UICC 8th edition) was reviewed from January 2010 to December 2015. The inclusion criteria were as follows: (1) patients with biopsy-confirmed primary NPC, (2) patients received cisplatin-based IC and radical IMRT, (3) patients received no previous treatments due to other cancers, and (4) patients with restored radiotherapy planning. The exclusion criteria were as follows: (1) failed to restore the radiotherapy planning (n = 14), (2) no available radiotherapy data in mosaïq system (n = 3), and (3) radiotherapy planning could not be extracted by the in-house script (n = 16). **Supplementary Figure S1** presented the patient inclusion flowchart. Finally, 434 patients were included, of which 247 patients (IC ± CC cohort) were treated with IC + CCRT or IC + IMRT and 187 (IC ± CC + AC cohort) were treated with IC + CCRT + AC or IC + IMRT + AC.

The characteristics of the patients were collected from the hospital information systems. The chemotherapy and radiotherapy regimens are described in **Supplementary S1**. The primary endpoints included RFS, locoregional RFS (LRFS), distant metastasis-free survival (DMFS), and OS. RFS was defined as the time from treatment until the diagnosis of a recurrent disease. LRFS was defined as the time from treatment to local or regional recurrence. DMFS was defined as the time from treatment to data of distant recurrence. OS was defined as the date from treatment to death from any cause.

**Dosimetric Parameter Extraction and Dosimetric Signature Building**

The radiotherapy planning data were restored from the mosaïq system (Elekta Medical Systems, Sunnyvale, CA, USA) and were transferred to the treatment planning system Raystation. A total of 808 dosimetric parameters were calculated from the target volume for each patient through our in-house script (14), including D1-100, D1 cc-5 cc, D1min cc-5min cc. Dv% was described as the minimal dose delivered into v% of the target volume. Dv cc and Dvmin cc are the maximal and minimal dose exposed in the absolute target volume v cc. Gross tumor volume (GTV) contains the gross tumor volume of the nasopharynx (GTVnx) and gross tumor volume of regional lymph node (GTVnd). The planning GTVnx/nd (PGTVnx/nd) was obtained by expanding the corresponding GTVnx/nd with an expanded margin of 3 mm. GTVnx, GTVnd, PGTVnx, and PGTVnd were the target volumes. The least absolute shrinkage and selection operator (LASSO) algorithm was applied to select the dosimetric parameters that associated with RFS among the above-mentioned 808 features. The selected parameters were weighted by their respective coefficients and were calculated as a linear combination to construct the planning score for each patient.

**Development and Validation of Nomogram**

Univariate and multivariate Cox proportional hazards regression model was applied to achieve the candidate variables. A nomogram predicting RFS was constructed based on the candidate variables of 247 patients from the IC ± CC cohort and was internally validated by performing 1,000 bootstrap resamples. The concordance index (C index) was utilized to evaluate the predictive performance of the nomogram. In addition, a calibration curve was plotted to compare the actual probabilities against the prediction probabilities of the nomogram.

**Classification of Patients Into Low- or High-Risk Subgroup**

We computed the nomogram risk score for each patient by linear predictor function “predict” in R, which was applied for prediction based on the results of Cox model fitting functions (14). The cutoff value of the nomogram risk score was calculated by the X-tile software (version 3.6.1; Yale University, New Haven, CT, USA), which produced the largest χ² value in the Mantel–Cox test (15). The 247 patients were divided into low- or high-risk group according to the optimal cutoff risk score, and the same classification criterion was performed on the 187 patients.

**Statistical Analysis**

All statistical analyses were performed on R software (version 3.5.2), MedCalc (version 15.6), and SPSS (version 22.0). The t-test was used for comparison between categorical variables, and chi-square test was used for comparison between categorical variables. All dosimetric and clinical data were normalized using log-transform before analysis. Kaplan–Meier curves were plotted by MedCalc and compared by log-rank test. R packages were used as follows: “glmnet” for LASSO–Cox regression, “Rms” for nomogram and calibration curves, “Hmisc” for correlation matrix, and “Hemtest” (Heatmap Illustrator, version 1.0) for heat map. “ipw” (**Supplementary S2**) was applied for estimating the inverse probability weights to control confounding (16).

**RESULTS**

**Patient Characteristics**

Patient characteristics and cycles of IC were compared between the CC and non-CC cohorts and between the AC and non-AC cohorts (**Table 1**). No significant differences were observed between the two cohorts besides age (p = 0.001) and hemoglobin (p = 0.04) in the IC ± CC cohort. Forty (9.2%) patients were at stage II. After a median follow-up of 50 months (range, 2–113 months), 44 patients experienced locoregional recurrence, 64 patients experienced distant recurrence, and 99 patients died of NPC. For the whole dataset, the 5-year LRFS, DMFS, and OS rates were 85.5, 82.4, and 83.8%, respectively.

**Dosimetric Signature Construction**

Of the 808 dosimetric parameters, 404 metrics were extracted from the GTV, and the remaining 404 were extracted from the planning gross tumor volume (PGTV). After LASSO, three GTV parameters (GTVnd_1.2cc, GTVnd_4.7cc, and GTVnd_4.8cc) and six PGTV parameters (PGTVnx_D98, PGTVnx_D99, PGTVnd_0.3ccmin, PGTVnd_0.6ccmin, PGTVnx_CI, and PGTVnx_HI) associated with RFS were applied to construct the dosimetric signature. The dosimetric signature equation was as follows:

\[
\text{Dosimetric signature} = -0.004 \times \text{PGTVnx}_D^98 -0.093 \times \text{PGTVnx}_D^99 - 0.017 \times \text{PGTVnd}_0.3ccmin - 0.087
\]
TABLE 1 | Characteristics of all patients (n = 434) with nasopharyngeal carcinoma.

| IC ± CC cohort | IC ± CC + AC cohort |
|----------------|-------------------|
|               | (n = 67) | (n = 180) | P-value | (n = 59) | (n = 128) | P-value |
| Age (years)    | 53.3 ± 11.3 | 46.6 ± 10.3 | 0.001 | 48.5 ± 10.7 | 44.5 ± 9.9 | 0.344 |
| Sex            | 0.274     |           |       | 0.102     |           |       |
| Male           | 46 (69)   | 136 (76)  |       | 32 (54)   | 53 (41)   |       |
| Female         | 21 (31)   | 44 (24)   |       | 27 (46)   | 75 (59)   |       |
| BMI (kg/m²)    | 22.3 ± 3  | 22.6 ± 3.1| 0.545 | 22.5 ± 2.7| 22.5 ± 3.9| 0.678 |
| Family history | 0.741     |           |       | 0.512     |           |       |
| No             | 57 (85)   | 150 (83)  |       | 46 (78)   | 105 (82)  |       |
| Yes            | 10 (15)   | 30 (17)   |       | 13 (22)   | 23 (18)   |       |
| Cigarette smoking | 0.619 |           |       | 0.635     |           |       |
| No             | 30 (45)   | 87 (48)   |       | 34 (58)   | 69 (54)   |       |
| Yes            | 37 (55)   | 90 (52)   |       | 25 (42)   | 59 (48)   |       |
| Alcohol consumption | 0.906 |           |       | 0.997     |           |       |
| No             | 50 (75)   | 133 (74)  |       | 47 (80)   | 102 (80)  |       |
| Yes            | 17 (25)   | 47 (26)   |       | 12 (20)   | 26 (20)   |       |
| Hb (g/L)       | 139.0 ± 16.4 | 143.2 ± 14.4 | 0.040 | 137.9 ± 16 | 136.6 ± 22.9 | 0.910 |
| Neutrophil count (x10⁹/L) | 4.1 ± 1.6 | 6.9 ± 0.8 | 0.386 | 3.7 ± 1.4 | 3.8 ± 1.3 | 0.533 |
| Lymphocyte count (x10⁹/L) | 1.6 ± 0.6 | 1.7 ± 0.6 | 0.321 | 1.5 ± 0.7 | 1.7 ± 0.7 | 0.333 |
| NLR            | 2.8 ± 1.6 | 5.8 ± 3.3 | 0.477 | 2.7 ± 0.4 | 2.5 ± 1.3 | 0.457 |
| LDH (IU/L)     | 175.4 ± 57.9 | 179.5 ± 75 | 0.941 | 170.1 ± 44 | 171.8 ± 48.5 | 0.591 |
| AJCC/UICC 8th TNM stage | 0.730 | 0.672 |       | 0.568     |           |       |
| II             | 6 (10)    | 20 (11)   |       | 4 (7)     | 10 (8)    |       |
| III            | 25 (37)   | 73 (41)   |       | 26 (44)   | 64 (50)   |       |
| IVa            | 36 (53)   | 87 (48)   |       | 29 (49)   | 54 (42)   |       |
| T stage        | 0.134     |           |       | 0.600     |           |       |
| T1             | 12 (18)   | 21 (12)   |       | 7 (12)    | 19 (15)   |       |
| T2             | 4 (6)     | 25 (14)   |       | 8 (14)    | 19 (15)   |       |
| T3             | 23 (34)   | 74 (41)   |       | 34 (57)   | 64 (50)   |       |
| T4             | 28 (42)   | 60 (33)   |       | 10 (17)   | 26 (20)   |       |
| N stage        | 0.219     |           |       | 0.600     |           |       |
| N0             | 2 (3)     | 1 (0)     | 0 (0) | 1 (0)     |           |       |
| N1             | 11 (16)   | 46 (26)   | 7 (12) | 20 (16)   |           |       |
| N2             | 39 (58)   | 96 (53)   | 30 (51) | 70 (55)   |           |       |
| N3             | 15 (22)   | 37 (21)   | 22 (36) | 37 (29)   |           |       |
| GTVnx (cc)     | 45.8 (25.8-63.9) | 49.9 (33.1-74.7) | 0.240 | 31.9 (21.4-55.5) | 37.5 (25.7-63.2) | 0.210 |
| GTVnd (cc)     | 11.1 (5.8-22.2) | 12.8 (7.1-27.9) | 0.254 | 10.6 (6.9-20.7) | 14.2 (8.2-30.7) | 0.099 |
| WHO histological type | 0.246 |            |       | 0.419     |           |       |
| Keratinizing SqCC | 0 (0)   | 0 (0)     | 0 (0) | 1 (1)     |           |       |
| Non-keratinizing, differentiated | 60 (90) | 166 (82) | 54 (92) | 106 (83) |           |       |
| Non-keratinizing, undifferentiated | 4 (6) | 12 (7) | 3 (5) | 15 (12) |           |       |
| Unspecified    | 3 (4)     | 2 (1)     | 2 (3) | 6 (5)     |           |       |
| IC cycles      | 0.33      |           |       | 0.292     |           |       |
| <2 cycles      | 35 (52)   | 92 (51)   | 40 (69) | 78 (61)   |           |       |
| ≥2 cycles      | 32 (48)   | 88 (49)   | 18 (31) | 50 (39)   |           |       |

Data are shown as mean (standard deviation), median (interquartile ranges), or number (percentage).
BMI, body mass index; Hb, hemoglobin; PLT, platelets; NLR, neutrophil lymphocyte ratio; LDH, lactate dehydrogenase; GTVnx, nasopharynx gross tumor volume; GTVnd, lymph node gross tumor volume; cc, cubic centimeter; CC, concurrent chemotherapy; IC, induction chemotherapy; AC, adjuvant chemotherapy.

PGTVnd_0.6ccmin + 0.053 * GTVnd_1.2cc + 0.001 * GTVnd_4.7cc + 0.145 * GTVnd_4.8cc - 0.187 * PGTVnx_CI + 0.111 * PGTVnx_HI

Association Between Dosimetric Parameters and Tumor-Related Data
In the IC ± CC cohort, the univariate Cox analysis identified T stage, N stage, TNM stage, and volume of GTVnd as tumor-related risk factors of RFS (Table 2). We then plotted the correlation matrix and heat map to illustrate the association between the nine dosimetric parameters and tumor-related data in Supplementary Figure S2 and Figure 2, respectively. The results showed that T stage was significantly associated with four dosimetric parameters, including PGTVnx_CI, PGTVnx_HI, PGTVnx_D98, and GTVnx_D99 (all P ≤ 0.001). N stage and GTVnd_Volume were associated with the same five dosimetric parameters, including PGTVnd_0.3ccmin, GTVnd_4.8cc, GTVnd_0.6ccmin, GTVnd_1.2cc, and GTVnd_4.7cc (all P ≤ 0.05). TNM stage was associated with six dosimetric parameters, including PGTVnx_D99, PGTVnx_D98,
IC cycles 1.413 (0.899–1.012), NLR 1.000 (0.992–1.009), LDH (IU/L) 1.001 (0.998–0.998), and GTVnx (cc) 1.002 (0.995–1.010). 

**Development of the Prognostic Nomogram**

A subsequent multivariate Cox analysis showed that dosimetric signature (HR, 4.278, 95% CI: 2.36–7.755) and TNM stage (HR, 1.944, 95% CI: 1.163–3.255) were two independent risk factors for RFS (Table 2). As age is a key consideration in the NPC treatment, a nomogram incorporating age, TNM stage, and dosimetric signature to predict the 3- and 5-year RFS was developed in the IC ± CC cohort (Figure 3A). The nomogram was internally validated by bootstrapping for 1,000 times. The unadjusted and bootstrapping-corrected C-index values of the nomogram in predicting RFS were 0.712 (95% CI: 0.647–0.777) and 0.719 (95% CI: 0.658–0.78), respectively. The calibration curves showed a good agreement between the predicted 3- and 5-year RFS probabilities by nomogram and actual 3- and 5-year RFS (Figures 3B, C).

**Chemotherapy in Patient Groups With Low and High Risk**

We performed a subset analysis to evaluate the survival benefit of CC in low- and high-risk groups. According to the optimal cutoff risk score of 0.60 identified by the X-tile plot, the patients were stratified into low-risk group (<0.60) and high-risk groups (≥0.60). The Kaplan–Meier curves showed significantly different LRFS, DMFS, and OS between the two groups (Supplementary Figure S3). In the low-risk group, IC + CCRT was superior to IC + IMRT in terms of LRFS (HR, 0.27; 95% CI: 0.062–1.248; P = 0.03) and OS (HR, 0.363; 95% CI: 0.111–1.184; P = 0.036) but not DMFS (HR, 0.598; 95% CI: 0.216–1.651; P = 0.26) (Table 3 and Figures 4A–C). CC was associated with a 9.4% increase of 5-year LRFS and an 8.8% increase of 5-year OS (Supplementary Figure S4). IC + CCRT + AC was not superior to IC + IMRT + AC in terms of LRFS, DMFS, and OS (P = 0.145, 0.506, and 0.093, respectively) (Table 3 and Figures 4G–I).

**TABLE 2 | Identification of risk factors of recurrence-free survival by univariate and multivariate analysis in induction chemotherapy ± concurrent chemotherapy cohort.**

| Risk Factor                      | Univariate Cox regression (HR [95% CI]) P-value | Multivariate Cox regression (HR [95% CI]) P-value |
|----------------------------------|-----------------------------------------------|--------------------------------------------------|
| Age (years)                      | 1.013 (0.986–1.038) 0.316                      | 1.018 (0.992–1.045) 0.110                        |
| Sex (male vs. female)            | 0.760 (0.409–1.141) 0.384                      | –                                                |
| BMI (kg/m²)                      | 0.988 (0.954–1.023) 0.494                      | –                                                |
| Family history of cancer (yes vs. no) | 0.703 (0.319–1.550) 0.382                      | –                                                |
| Cigarette smoking (yes vs. no)   | 1.202 (0.712–2.029) 0.492                      | –                                                |
| Alcohol consumption (yes vs. no) | 0.784 (0.422–1.456) 0.441                      | –                                                |
| Hb (g/L)                         | 0.998 (0.985–1.012) 0.798                      | –                                                |
| PLT (x10⁹/L)                     | 0.999 (0.995–1.004) 0.806                      | –                                                |
| Neutrophil count (x 10⁹/L)       | 1.001 (0.992–1.010) 0.826                      | –                                                |
| Lymphocyte count (x 10⁹/L)       | 1.413 (0.899–2.221) 0.134                      | –                                                |
| DR ratio                         | 1.000 (0.992–1.009) 0.961                      | –                                                |
| LDH (IU/L)                       | 1.001 (0.998–1.004) 0.415                      | –                                                |
| NLR                              | 2.236 (1.356–3.866) 0.002                      | 1.944 (1.161–3.255) 0.012                        |
| T stage                          | 1.426 (1.030–1.973) 0.032                      | 1.203 (0.824–1.757) 0.362                        |
| N stage                          | 2.066 (1.358–3.145) 0.001                      | 1.233 (0.716–2.123) 0.637                        |
| GTVnx (cc)                       | 1.002 (0.994–1.010) 0.632                      | –                                                |
| GTVnd (cc)                       | 1.010 (1.008–1.015) <0.001                     | 1.004 (0.998–1.010) 0.246                        |
| IC + CCRT vs. IC + IMRT          | 0.467 (0.276–0.792) 0.005                      | 0.607 (0.352–1.049) 0.071                        |
| IC cycles                        | 1.113 (0.753–1.647) 0.591                      | –                                                |
| Dosimetric signature             | 4.825 (2.680–8.688) <0.001                     | 4.278 (2.360–7.755) <0.001                       |

HR, hazard ratio; CI, confidence intervals; BMI, body mass index; Hb, hemoglobin; PLT, platelets; NLR, neutrophil lymphocyte ratio; LDH, lactate dehydrogenase; GTVnx, nasopharynx gross tumor volume; GTVnd, lymph node gross tumor volume; cc, cubic centimeter; IMRT, intensity-modulated radiotherapy.

Statistically significant values (P ≤ 0.05) were formatted in bold.

---

**FIGURE 2 | A heat map of associations between selected dosimetric parameters and tumor-related data.**

*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
The aforementioned results were confirmed by IPTW (data not shown) to control confounding. We further explored the additional survival benefit of AC in both the low- and high-risk groups. In the low-risk group, IC + IMRT + AC was not superior to IC + IMRT in terms of 0.236, respectively (Table 3 and Figures 4D–F, J–L). The aforementioned results were confirmed by IPTW (data not shown) to control confounding.

### TABLE 3 | Effects of concurrent chemotherapy on LRFS, DMFS, and OS in different subgroups according to the risk score of the nomogram.

|                | CC cohort (n = 247) | Non-CC cohort (n = 247) | LRFS | DMFS | OS |
|----------------|---------------------|-------------------------|------|------|----|
|                |                     |                         | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) |
| Low risk       | 141                 | 47                      | 0.030  | 0.270 (0.062–1.248) | 0.260  | 0.598 (0.218–1.651) | 0.036  | 0.363 (0.111–1.184) |
| High risk      | 39                  | 20                      | 0.200  | 0.526 (0.175–1.580) | 0.874  | 0.921 (0.325–2.612) | 0.668  | 1.260 (0.446–3.562) |
| All patients   | 180                 | 67                      | 0.004  | 0.329 (0.130–0.832) | 0.185  | 0.635 (0.303–1.333) | 0.093  | 0.544 (0.243–1.220) |
| IC + AC cohort (n = 187) |                 |                         |       |      |    |
| Low risk       | 74                  | 31                      | 0.145  | 0.287 (0.042–1.940) | 0.506  | 0.605 (0.122–2.993) | 0.093  | 0.378 (0.106–1.354) |
| High risk      | 54                  | 28                      | 0.148  | 2.463 (0.889–6.982) | 0.236  | 1.814 (0.745–4.418) | 0.022  | 4.735 (1.784–12.566) |
| All patients   | 128                 | 59                      | 0.757  | 1.163 (0.459–2.948) | 0.590  | 1.252 (0.571–2.746) | 0.544  | 1.287 (0.589–2.813) |

CC, concurrent chemotherapy; IC, induction chemotherapy; AC, adjuvant chemotherapy; LRFS, locoregional recurrence-free survival; DMFS, distant metastasis-free survival; OS, overall survival. Statistically significant values (*P* ≤ 0.05) were formatted in bold.
LRFS, DMFS, and OS (P = 0.812, 0.436, and 0.851, respectively); IC + CCRT + AC was not superior to IC + CCRT in terms of LRFS, DMFS, and OS (P = 0.862, 0.316, and 0.771, respectively) (Supplementary Table S1 and Supplementary Figures S5A–C, G–I). In the high-risk group, IC + IMRT + AC was superior to IC + IMRT in terms of LRFS (HR, 0.272; 95% CI 0.076–0.969; P = 0.042) but not DMFS and OS (P = 0.341 and 0.119, respectively) (Supplementary Table S1 and Supplementary Figure S5D–F), AC was associated with a 33.6% increase of 5-year LRFS (Supplementary Figure S4), and IC + CCRT + AC was not superior to IC + CCRT in terms of LRFS, DMFS, and OS (P = 0.757, 0.779, and 0.964, respectively) (Supplementary Table S1 and Supplementary Figures S5J–L).
DISCUSSION

Based on dosimetric parameters derived from the IMRT plan in patients with stage II–IVa NPC treated with IC followed by IMRT, we constructed a novel nomogram to quantify the risk of RFS of individuals. Using the optimal cutoff risk score calculated by the model, we successfully categorized the patients into low- and high-risk subgroups with significantly different survival outcomes. Patients with a low risk could benefit from CC by improving the 5-year LRFS and OS, while patients with a high risk could choose IC + IMRT + AC to obtain an improved 5-year LRFS.

A total of 808 dosimetric factors were extracted and reduced to a panel of nine potential prognosticators by using a LASSO–Cox. LASSO is a robust regression technique for penalized analysis and variable selection from the mass data of dosimetric parameters (14, 17, 18). Cox regression analysis recognized the dosimetric signature, composed of nine factors, as an independent risk factor of RFS even after adjustment for age, TNM stage, and other confounders. Dosimetric signatures were essentially generated from radiotherapy plans based on contours that are a product of disease extent (TNM stage and/or disease volume). As potential confounders (19), disease extent should be incorporated into a regression analysis (Table 2). Unexpectedly, it was TNM stage, not disease volume, that associated with RFS. The reasons for this result can be explained by the inadequate tumor coverage (reflected by the dosimetric signature) that were mainly from TNM stage (adherence to adjacent critical structures) rather than disease volume in the IMRT era (8). It is clinically challenging to strike a balance between the risk of recurrence due to inadequate tumor coverage and radiation complications of the adjacent critical structures.

Considering that inadequate tumor coverage is mainly from the disease extent in the IMRT era, the association between dosimetric signature and tumor characteristics was investigated in this study. A higher T stage was related to higher conformal index and homogeneity index. With the primary tumor infiltrating deeply, the margins between gross tumor and nearby critical OARs become narrower and narrower. Because of the radiation safety principle “as low as reasonably practicable” for critical OARs in clinical practice (8), a steeper dose fall-off outside the target volume and a better conformal index are prone to be observed in advanced T stage patients (20, 21). As a compromise to the critical OARs, inhomogeneous target dose distribution is a strategy without an apparent dosimetric inadequacy of target volumes (22). However, inhomogeneous plans may be attributable to more cold spots (23), as the representative factors of cold spots, PGTVnx_D98 or PGTVnx_D99, seem to be ignored by PGTVnx_D95 in plan evaluation (24). As for N stage and GTVnd_Volume, we found that all the dose factors were associated with the two regardless of the volume and dose. It may be due to the progressive deformation of neck soft tissue structures from intrafraction motion (25). In addition, a recent study suggested that positive regional lymph nodes should be focused prior to primary tumor in NPC radiotherapy (14).

Our dosimetric signature does not contain D95 that is often used in the radiotherapy area. A plausible explanation for this might be that more attention on D95 in daily clinical practice limits its power. Definitive chemoradiotherapy is recommended by the 2021 National Comprehensive Cancer Network guidelines for stage II–IVa NPC patients. Because the quality of IMRT plans mainly relies on the experience of the dosimetrist (26), our dosimetric signature performed individualized risk quantification of IMRT plan for RFS, making it a surrogate for plan quality. It is therefore plausible that the chemotherapy benefit may be making up for poor radiation planning.

We found that CC was not a significant prognosticator of survival outcomes in the multivariate analysis. However, a subgroup analysis showed that CC can benefit patients with low risk instead of high risk in improving LRFS and OS. This finding is consistent with a gene expression-based signature study (27), a clinical experience-based report (28), and a dose–effect analysis (29). However, the results differed from other previous studies (30, 31), possibly because of the patients treated with 2D (31) or no comparison of radiotherapy alone in the IMRT subgroup analysis (30). We expected the results of an ongoing phase 3 clinical trial (NCT02633202) comparing CCRT with IMRT alone to establish the role of CC in the IMRT era.

Our study showed that AC can benefit high-risk patients treated with IC + IMRT in terms of LRFS. The modality of IC + IMRT + AC may be a promising strategy for the high-risk group in the IMRT era. A phase III trial proved that AC with intravenous cisplatin and 5-fluorouracil failed to improve failure-free survival and OS after CCRT but increased the toxic effects in NPC (32). However, efforts have been made to find the candidates for AC. A postradiotherapy plasma Epstein–Barr virus DNA screening failed to identify patients with positive treatment effects (33). Interestingly, a benefit of distant failure and overall survival was obtained in high-risk patients with modified oral chemotherapy agents (34, 35). Compared to platin-based chemotherapy, this kind of metronomic chemotherapy was associated with less toxicities, good compliance, and potential activation of immunity (36). A 2019 American Society of Clinical Oncology abstract (abstract no. 6046) reported that the total cumulative cisplatin dose (concurrent/induction/adjuvant) in multimodality therapy may be an independent prognosticator of LRFS and OS in locally advanced NPC. Therefore, the effect of CC was overemphasized, whereas the effect of AC was underestimated (34). Platin-based chemotherapy should be used post-IMRT instead of during IMRT in high-risk patients.

This study also has some limitations. Firstly, this was a retrospective study performed in a single center. Despite extensive adjustment, it is still possible that some amount of unmeasured confounders remains. Secondly, we did not consider the cumulative cisplatin dose because there was no consensus on the optimal cumulative cisplatin dose (29). Thirdly, EBV-DNA and its response after treatment is a major determinant of RFS and OS in patients with NPC (33, 37). However, the EBV-DNA in our datasets was measured at different time-points (e.g., post-IC, post-IMRT). A future update of the nomogram including the EBV data would strengthen the findings. Fourthly, setup error was not taken into consideration as a reason of limited daily CBCT data; a future study is needed to investigate the dosage inconsistency between treatment plan dose and the actual delivered dose which resulted from the error based on CBCT data. Finally, the clinical use of the nomogram can be tested if an external validation is executed.
CONCLUSIONS
According to our knowledge, this is the first study to explore the role of CC in the viewpoint of IMRT-based dosimetric factors. Our findings revealed that the nomogram can effectively classify patients with stage II–IVA NPC into subgroups with low and high risk of survival outcomes. A further analysis found that CC could improve LRR and OS for patients at low risk. Significantly, we identified that the high-risk patients could benefit from AC instead of CC. Prospective trials are needed to verify the positive treatment effect of CC and AC in low- and high-risk patients, respectively. Our nomogram will allow clinicians to make more informed decisions for better patient care.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Ethics Committee on Biomedical Research, West China Hospital of Sichuan University. The ethics committee waived the requirement of written informed consent for participation.

AUTHOR CONTRIBUTIONS
GL, KY: study design. KY, MZ, WX, ML, LZ, YL and QW: data collection. KY, JZ and QZ: data analysis. QZ, GL, and KY: data interpretation and writing.

FUNDING
This study is funded by the National Natural Science Foundation of China (grant no. 81472807).

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68:394–424. doi: 10.3322/caac.21492
2. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy Versus Radiotherapy in Patients With Advanced Nasopharyngeal Cancer: Phase III Randomized Intergroup Study 0099. J Clin Oncol (1998) 16:1310–7. doi: 10.1200/JCO.1998.16.4.1310
3. Chen Q, Wen Y, Guo L, Liu H, Huang PY, Mo HY, et al. Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial. JNCI: J Natl Cancer Inst (2011) 103:1761–70. doi: 10.1093/jnci/djr432
4. Li XY, Chen QY, Sun XS, Liu SL, Yan JJ, Guo SS, et al. Ten-Year Outcomes of Survival and Toxicity for a Phase III Randomised Trial of Concurrent Chemoradiotherapy Versus Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma. Eur J Cancer (2019) 110:24–31. doi: 10.1016/j.ejca.2018.10.020
5. Chen Y, Chan ATC, Le Q, Blanchard P, Sun Y, Ma J. Nasopharyngeal Carcinoma. Lancet (2019) 394:64–80. doi: 10.1016/S0140-6736(19)30956-0
6. Liu L, Fei Z, Chen M, Zhao L, Su H, Gu D, et al. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Induction Chemotherapy Plus Volumetric Modulated Arc Therapy Alone in the Treatment of Stage II–IVB Nasopharyngeal Carcinoma Patients: A Retrospective Controlled Study. Radiat Oncol (2018) 13(1):148. doi: 10.1186/s13032-018-1092-0
7. Kwong DL, Sham JS, Chua DT, Choy DT, Au GK, Wu PM. The Effect of Interruptions and Prolonged Treatment Time in Radiotherapy for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys (1997) 39:703–10. doi: 10.1016/S0140-6736(97)00339-8
8. Lee AW, Ng WT, Pan JH, Chiang CL, Poh SS, Choi HC, et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys (2019) 105:567–80. doi: 10.1016/j.ijrobp.2019.06.2540
9. Ng WT, Lee MC, Chang AT, Chan OS, Chan LI, Cheung FY, et al. The Impact of Dosimetric Inadequacy on Treatment Outcome of Nasopharyngeal Carcinoma With IMRT. Oral Oncol (2014) 50:506–12. doi: 10.1016/j.oraloncology.2014.01.017
10. Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS, et al. Clinical Outcomes and Patterns of Failure After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys* (2011) 79:420–8. doi: 10.1016/j.ijrobp.2009.11.024

11. Wolf D, Stieler F, Welzel G, Lorenz F, Abo-Madyan Y, Mai S, et al. Volumetric Modulated Arc Therapy (VMAT) vs. Serial Tomotherapy, Step- and-Shoot IMRT and 3D-Conformal RT for Treatment of Prostate Cancer. *Radiother Oncol* (2009) 93:226–33. doi: 10.1016/j.radonc.2008.08.011

12. Mayo CS, Yao J, Eisbruch A, Balter JM, Litzenberg DW, Matuszak MM, et al. Incorporating Big Data Into Treatment Plan Evaluation: Development of Statistical DVH Metrics and Visualization Dashboards. *Adv Radiat Oncol* (2017) 2:503–14. doi: 10.1016/j.adro.2017.04.005

13. Alfonso JC, Herrero MA, Nunez LA. Dose-Volume Histogram Based Decision-Support System for Dosimetric Comparison of Radiotherapy Treatment Plans. *Radiotherapy Oncol* (2015) 105:263, doi: 10.1016/j.ijrobp.2014.01-05-069-3

14. Yang K, Tian J, Zhang B, Li M, Xie W, Zou Y, et al. A Multidimensional Nomogram Combining Overall Stage, Dose Volume Histogram Parameters and Radiomics to Predict Progression-Free Survival in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma. *Oral Oncol* (2019) 98:85–91. doi: 10.1016/j.oraloncology.2019.09.022

15. Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. *Clin Cancer Res* (2004) 10:7252–9. doi: 10.1158/1078-0432.CCR-04-0713

16. Gelernter J, Sun Y, Lorch J, Balwin M, Hricak H, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients With Covid-19. *N Engl J Med* (2020) 25:2411–8. doi: 10.1056/NEJMoa2012410

17. Xu C, van der Schoaf A, Schilstra C, Langendijk JA, van T Veld AA. Impact of Statistical Learning Methods on the Predictive Power of Multivariate Normal Tissue Complication Probability Models. *Int J Radiat Oncol Biol Phys* (2012) 82:e677–84. doi: 10.1016/j.ijrobp.2011.09.036

18. Song J, Ji J, Dong D, Fang M, Zhong W, Wang K, et al. A New Approach to Predict Progression-Free Survival in Stage IV EGFR-Mutant NSCLC Patients With EGFR-TKI Therapy. *Clin Cancer Res* (2018) 24:5385–92. doi: 10.1158/1078-0432.CCR-17-2507

19. Ledezra DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, et al. Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals. *Ann Am Thorac Soc* (2019) 16:22–8. doi: 10.1513/AnnalsATS.201808-564PS

20. Miao J, Yan H, Tian Y, Ma P, Liu Z, Li M, et al. Reducing Dose to the Lungs Through Loosening Target Dose Homogeneity Requirement for Radiotherapy of non-Small Cell Lung Cancer. *J Appl Clin Med Phys* (2017) 18:169–76. doi: 10.1002/acm2.12208

21. Peng L, Xu C, Chen YP, Guo R, Mao YP, Sun Y, et al. Optimizing the Cumulative Cisplatin Dose During Radiotherapy in Nasopharyngeal Carcinoma: Is Concurrent Chemoradiotherapy Adequate? *Int J Radiat Oncol Biol Phys* (2004) 60:156–64. doi: 10.1016/j.ijrobp.2004.03.002

22. Lin AC, Lin J, Liang W, Ian J, Jiang R. Another Way to Estimate Outcome of Advanced Nasopharyngeal Carcinoma—Is Concurrent Chemoradiotherapy Neglected But Crucial Aspect. *Int J Radiat Oncol Biol Phys* (2010) 77:996–1001. doi: 10.1016/j.ijrobp.2009.06.006

23. Lin AC, Lin J, Liang W, Ian J, Jiang R. Another Way to Estimate Outcome of Advanced Nasopharyngeal Carcinoma—Is Concurrent Chemoradiotherapy Adequate? *Int J Radiat Oncol Biol Phys* (2004) 60:156–64. doi: 10.1016/j.ijrobp.2004.03.002

24. Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, et al. Statistical DVH Metrics and Visualization Dashboards. A Network Meta-Analysis. *Theranostics* (2017) 7:4825–35. doi: 10.7150/thno.21815

25. Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma: An Update of the MAC-NPC Meta-Analysis. *Lancet Oncol* (2015) 16:645–55. doi: 10.1016/S1470-2045(15)71026-9

26. Chen L, Hu C, Chen XZ, Hu GQ, Cheng ZB, Sun Y, et al. Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3 Multicentre Randomised Controlled Trial. *Lancet Oncol* (2012) 13:1663–71. doi: 10.1016/S1470-2045(11)70320-5

27. Chan ATC, Hui EP, Ngan RKC, et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. *J Clin Oncol Off J Am Soc Clin Oncol* (2018) 02018777847. doi: 10.1200/JCO.2018.77.7847

28. Twu CW, Wang WY, Chen CC, Liang KL, Jiang RS, Wu CT, et al. Metronomic Adjuvant Chemotherapy Improves Treatment Outcome in Nasopharyngeal Carcinoma Patients With Postradiation Persistently Detectable Plasma Epstein-Barr Virus Deoxyribonucleic Acid. *Int J Radiat Oncol Biol Phys* (2014) 89:21–9. doi: 10.1016/j.ijrobp.2014.01.052

29. Liu Y, Wang W, Twu C, Jiang RS, Liang KL, Wu CT, et al. Prognostic Impact of Adjuvant Chemotherapy in High-Risk Nasopharyngeal Carcinoma Patients. *Oral Oncol* (2017) 64:15–21. doi: 10.1016/j.oraloncology.2016.11.008

30. Bocci G, Kerbel RS. Pharmacokinetics of Metronomic Chemotherapy: A Neglected But Crucial Aspect. *Nat Rev Clin Oncol* (2016) 13:659–73. doi: 10.1038/nrclinonc.2016.64

31. Liu LT, Tang LQ, Chen QY, Zhang LL, Guo SS, Guo L, et al. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys* (2015) 93:862–9. doi: 10.1016/j.ijrobp.2015.08.003

32. Yang K, Li M, Zhu J, Zeng L, Tian J, Xie W, et al. Nomograms for Predicting Survival Outcomes in Intensity-Modulated Radiotherapy Era of Nasopharyngeal Carcinoma: A Study Based on Epstein-Barr Virus DNA Biological Responses. *Head Neck* (2021) 43(6):1838–47. doi: 10.1002/hed.26654

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Yang, Zhang, Zhang, Xie, Li, Zeng, Wang, Zhao, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.